Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Teva Pharmaceutical Industries Ltd. News release: Teva and Celltrion announce the availability of Truxima (rituximab-abbs) injection, the first biosimilar to Rituxan (rituximab) in the U.S. 2019 Nov 7.
2. AbbVie Inc. News release: Rinvoq (upadacitnib) meets primary and all ranked secondary endpoints in phase 3 study in psoriatic arthritis. 2019 Oct 31.